Filtered By:
Condition: Allergy

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 381 results found since Jan 2013.

Sustained Benefit with Repeated Treatments of OnabotulinumtoxinA in Post-Stroke Lower Limb Spasticity: 1-Year Open-Label Final Results from a Double-Blind, Placebo-Controlled, Phase 3 Trial (S7.002)
Conclusions:Improvements in MAS, CGI, and GAS scores were consistent and increased with repeated treatments of onabotulinumtoxinA over 1 year in patients with PSLLS. Study Supported By: AllerganDisclosure: Dr. Wein has received research support from Allergan, Bayer, Accorda, Astra Zeneca, and the National Institutes of Health. Dr. Geis has received personal compensation for activities with Allergan as a researcher and speaker. Dr. Ayyoub has received research support from Allergan, Merz, and Ipsen. Dr. Ochudlo has nothing to disclose. Dr. James has received personal compensation for activities with Allergan as an employee....
Source: Neurology - April 3, 2016 Category: Neurology Authors: Wein, T., Geis, C., Ayyoub, Z., Ochudlo, S., James, L., Pan, G., Bogucki, A., Dimitrova, R. Tags: Stroke Clinical Trials Source Type: research

Stroke in a global world: geographical differences in stroke subtypes and age at onset in two different populations from Europe and South America. (P1.094)
CONCLUSIONS: Changes in the prevalence of vascular risk factors and stroke subtypes can be expected with the ageing of populations. In order to reduce age and stroke-related burden, public health strategies should be implemented. Study Supported by:Disclosure: Dr. Casanova-Lanchipa has nothing to disclose. Dr. Carod has received personal compensation for activities with Allergan, Merck Sharp & Dohme, Lundbeck Research USA, Inc., Biogen Idec, Esteve, and Pfizer as a scientific advisory board member and/or speaker. Dr. Cruz-Ramirez has nothing to disclose. Dr. Sanchez-Perez has nothing to disclose. Dr. Siacara-Aguayo has...
Source: Neurology - April 8, 2015 Category: Neurology Authors: Casanova-Lanchipa, J., Carod, F., Cruz-Ramirez, L. M., Sanchez-Perez, N., Siacara-Aguayo, F., Gomez-Moreno, I., Gomez Romero, L., Coral, L., Trizotto, D., Moreira, C. Tags: Neuroepidemiology: Cerebrovascular Disease, Critical Care, Epilepsy, Child Neurology, and Sleep Source Type: research

Inpatient versus Outpatient Management of TIA or Minor Stroke: Clinical Outcome (P6.035)
Conclusion These findings suggest that routine hospitalization of patients with TIA or minor ischemic stroke does not positively affect short-term clinical outcome. Disclosure: Dr. Rothrock has received personal compensation for activities with Allergan and Boehringer-Ingleheim. Dr. Majidi has nothing to disclose. Dr. Burger has nothing to disclose. Dr. Leon-Guererro has nothing to disclose.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Rothrock, J., Majidi, S., Burger, K., Leon-Guererro, C. Tags: Telestroke and Other Innovations and TIA Source Type: research

Association of Serum Levels of Pentraxin-3, M-ficolin, and Surfactant Protein A with the Severity of Ischemic Stroke.
Abstract Stroke is one of the most leading causes of death and disability in the world. Complement system activation contributes to pathogenesis and neuronal damage following stroke. There are no defined biological serum markers to determine the severity of stroke in acute phases. The purpose of current study was to determine the association of three complement activators, namely Pentraxin-3 (PTX3),M-ficolin, and Surfactant protein A (SPA) with the severity of ischemic stroke. This cross-sectional study was done on 82 patients diagnosed with ischemic stroke at 24-96 hours of initiation of the clinical symptoms dur...
Source: Iranian Journal of Allergy, Asthma and Immunology - April 1, 2017 Category: Allergy & Immunology Authors: Kouchaki E, Babamohammadi A, Nikoueinejad H, Sehat M Tags: Iran J Allergy Asthma Immunol Source Type: research

Childhood stroke: comparison of strokes identified in administrative databases with those identified in a population-based study (P1.072)
Conclusions: We found differences in distribution of both age and stroke type between a population-based physician-confirmed child stroke database and those identified through two administrative databases using ICD-9 codes having large positive predictive value. It appears there may be uncertainty regarding coding of stroke events in administrative databases. Using data obtained from physician-verified databases is optimal for inferential analysis.Disclosure: Dr. Taylor has nothing to disclose. Dr. Khoury has nothing to disclose. Dr. Xu has nothing to disclose. Dr. Sucharew has nothing to disclose. Dr. Alwell has nothing t...
Source: Neurology - April 8, 2015 Category: Neurology Authors: Taylor, J., Khoury, J., Xu, Y., Sucharew, H., Alwell, K., Moomaw, C., Horn, P., Yeramaneni, S., Peariso, K., Khatri, P., Broderick, J., Kissela, B., Kleindorfer, D. Tags: Cerebrovascular Disease and Interventional Neurology: Epidemiology Source Type: research

Chronic rhinosinusitis increased the risk of stroke: A 5‐year follow‐up study
ConclusionsPatients with CRS were at higher risk for stroke occurrence during the 5 year follow‐up. Level of Evidence2b. Laryngoscope, 2013
Source: The Laryngoscope - February 1, 2013 Category: ENT & OMF Authors: Jiunn‐Horng Kang, Chuan‐Song Wu, Joseph J. Keller, Herng‐Ching Lin Tags: Allergy/Rhinology Source Type: research

Patients with Stroke and Dysphagia: Demographics and Trends in Percutaneous Endoscopic Gastrotomy Tube Use in Stroke Patients in the United States from 1988-2010 (P01.219)
CONCLUSIONS: The use of PEG tubes has increased over time in US hospital admissions for acute stroke, and was associated with multiple comorbidities, greater length of stay and age > 74. This shows the increasing awareness of post-stroke dysphagia.Disclosure: Dr. Johnson has nothing to disclose. Dr. Dubinsky has received personal compensation for activities with Allergan, Inc. Dr. Dubinsky has received research support from Allergan Pharmaceuticals, Medivation Pharmaceuticals, and from the National Institutes of Health.
Source: Neurology - February 14, 2013 Category: Neurology Authors: Johnson, K., Dubinsky, R. Tags: P01 Cerebrovascular Disease I Source Type: research

The Role of Discharge Disposition in the Interventional Management of Stroke (IMSIII) Trial (P1.062)
CONCLUSIONS:Subjects who were discharged home or to an IRF were significantly associated with having a favorable outcome compared to those who were discharged to a SNF.Disclosure: Dr. Belagaje has nothing to disclose. Dr. Gupta has received personal compensation for activities with Stryker Neurovascular, Rapid Medical, and Covidien. Dr. Foster has nothing to disclose. Dr. Kissela has received personal compensation for activities with Allergan, Inc., AbbVie, and Reata Pharmaceuticals. Dr. Broderick has received personal compensation for activities with Pfizer as a consultant. Dr. Broderick has received research support from Genentech Inc.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Belagaje, S., Gupta, R., Foster, L., Kissela, B., Broderick, J. Tags: Cerebrovascular Disease and Interventional Neurology: Epidemiology Source Type: research

Effect of early use of AbobotulinumtoxinA (Dysport(R)) after stroke on spasticity progression: first results of a pilot study (P4.032)
Conclusions:Median time between first injection (administered in patients 2–12 weeks post-stroke, MAS ≥2) and appearance of reinjection criteria (signs of symptomatic spasticity) was statistically significantly longer with aboBoNT-A compared with placebo. Safety profile was consistent with the known profile of aboBoNT-A.Study Supported by:Study supported by IpsenDisclosure: Dr. Rosales has received personal compensation for activities with Ipsen and Pfizer as a scientific advisory board member and consultant. Dr. Goh has received personal compensation for activities with Sanofi Genzyme as a moderator. Dr. Kumthorn...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Rosales, R., Goh, K. J., Kumthornthip, W., Mazlan, M., Latif, L. A., De Los Santos, M. M., Chotiyarnwong, C., Tanvijit, P., Balcaitiene, J., Maisonobe, P., Kong, K.-H. Tags: Neuro-rehabilitation: Motor Recovery and Spasticity Treatment Source Type: research

Hyaluronic acid and Regenerative medicine: New insights into the stroke therapy.
Abstract Stroke is known as one of very important public health problems which are related to a societal burden and tremendous economic. It has been showed, there are few therapeutic approaches in the treatment of this disease. In this regard, present therapeutic platforms aim to obtain neuroprotection, reperfusion, and neurorecovery. Among these therapies, regenerative medicine-based therapies have been appeared as new ways in stroke therapy. Hyaluronic acid (HA) is a new candidate which could be applied as regerenative medicine-based therapy in the treatment of stroke. HA is a glycosaminoglycan which is formed o...
Source: Current Molecular Medicine - March 24, 2020 Category: Molecular Biology Authors: Shahi M, Mohammadnejad D, Karimipour M, Rasta SH, Rahbarghazi R, Elahi AA Tags: Curr Mol Med Source Type: research

Occurrence and relative risk of stroke in incident and prevalent contemporary rheumatoid arthritis
Conclusion The magnitude of stroke risk is lower than for ischaemic heart disease in RA, and the evolvement of this risk from RA diagnosis may be slower. This suggests different driving forces behind these two RA co-morbidities and has implications for the clinical follow-up of patients with RA.
Source: Annals of the Rheumatic Diseases - February 25, 2013 Category: Rheumatology Authors: Holmqvist, M., Gransmark, E., Mantel, A., Alfredsson, L., Jacobsson, L. T. H., Wallberg-Jonsson, S., Askling, J. Tags: Immunology (including allergy), Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Rheumatoid arthritis Clinical and epidemiological research Source Type: research

Satisfaction With Botulinum Toxin Treatment In Post-Stroke Spasticity: Results From Two Cross-Sectional Surveys Of Patients And Physicians (P1.143)
CONCLUSIONS: Overall, patient satisfaction with botulinum toxin treatment for post-stroke spasticity is high, but declines toward the end of each injection cycle. Hence, many patients would prefer shorter injection intervals than the standard 12 weeks. While most physicians are satisfied with botulinum toxin injections for post-stroke spasticity, many feel that a proportion of patients might gain additional benefit from shorter intervals and higher doses than those currently permitted.Study Supported by: Merz Pharmaceuticals GmbHDisclosure: Dr. Bensmail has received personal compensation for activities with Merz Pharma, Ip...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Bensmail, D., Hanschmann, A. Tags: Cerebrovascular Disease and Interventional Neurology: Rehabilitation and Recovery Source Type: research

OSA Is Under-Reported In Patients Admitted With Acute Stroke (P5.280)
CONCLUSION: The prevalence of OSA as a secondary diagnosis of those admitted with stroke was less than 1/3 that which would be predicted based on community prevalence. Since OSA is felt to be a risk factor for stroke, better detection of OSA in patients admitted for stroke is needed.Disclosure: Dr. Shorten has nothing to disclose. Dr. Dubinsky has received personal compensation for activities with Allergan Inc. Dr. Dubinsky has received research support from Allergan Inc., Medevation Pharmaceuticals, and from the National Institutes of Health.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Shorten, S., Dubinsky, R. Tags: Sleep: Sleep Related Breathing Source Type: research

Racial And Ethnic Disparities In Stroke. Declining Age At Time Of Stroke. Analysis Of The Nationwide Inpatient Sample 1988-2010 (S12.002)
CONCLUSIONS: In this longitudinal national sample age at time of stroke became younger for blacks and Hispanics, but not Caucasians. This has increased the disparity of age of onset between blacks and Caucasians. Over time the number of comorbidities have increased, perhaps due to upcoding by hospitals rather than worsening health status of the population.Disclosure: Dr. Costa has nothing to disclose. Dr. Dubinsky has received personal compensation for activities with Allergan Inc. Dr. Dubinsky has received research support from Allergan Inc., Medevation Pharmaceuticals, and from the National Institutes of Health.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Costa, C., Dubinsky, R. Tags: Cerebrovascular Disease and Interventional Neurology: Epidemiology and Risk Factors Source Type: research

Outcome Assessment of Acute Ischemic Stroke Patients after Treatment with IV tPA in a Rural Health System (P02.026)
CONCLUSIONS: Patients administered IV tPA for acute ischemic stroke in a rural hospital setting experienced 90-day outcomes similar to those of historical controls. Further attempts to reduce the number of in-hospital complications and reduce time to administration may result in improved patient outcomes.Supported by: Joan Curran Memorial Summer Fellowship in Neurosciences through Gundersen Lutheran Medical Foundation.Disclosure: Dr. Milsap has nothing to disclose. Dr Aldred has received personal compensation for activities with Teva, Ipsen, and Allergan as a speaker and from Teva and Abbot as an advisor. Dr. Aldred has re...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Milsap, A., Aldred, J., Skaar, J. Tags: P02 Cerebrovascular Disease II Source Type: research